Christopher Bissonnette
CDL West @ Creative Destruction Lab
Chicago, United States
Christopher Bissonnette is a seed investor at Creative Destruction Lab in Chicago focused on Software and Enterprise Software. Christopher Bissonnette is the President at Pallasite Ventures. Whether it’s as a neuroscientist researching Alzheimer disease therapies, or as an executive in control of investment portfolios and commercial real estate, Christopher has taken an analytical approach throughout his career. This varied experience has given him valuable insightinto Chicago’s most desirable locations for advertisers and a deep understanding of the complex leasing and permitting restrictions involved. As co-founder and CFO of GreenSigns Chicago, Christopher helps ensure that our advertisers and landlords receive the best possible value. As an avid biker and hiker, he helps ensure a high-energy level throughout the GreenSigns’ office.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Christopher Bissonnette invests in
Stages Christopher Bissonnette invests in
Countries Christopher Bissonnette invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $653k–$5M
- Series A
- $15M–$20M
Investment Focus
Industry
- Software 2 (25%)
- Enterprise Software 2 (25%)
- Information Technology 2 (25%)
- CRM 1 (13%)
- Video 1 (13%)
Stage
- Seed 5 (63%)
- Series A 1 (13%)
Country
- Canada 4 (50%)
- United States 1 (13%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $20M / Series A / Dec 05, 2023 | |
|
Ionomr
|
Ionomr is pioneering and commercializing the world's most advanced ion-exchange materials. These provide an enabling platform for clean tech solutions after more than five decades of stagnation in available materials. Using our deep knowledge of scalable electrochemical systems, we enable more efficient systems that will lead to thedecarbonization of the planet for future generations. To date, electrochemical applications in the clean tech realm use materials that contain toxic fluorinated chemicals (PFCs). PFCs leach into water sources and bioaccumulate for hundreds of years, having a dire impact on human health and the entire ecosystem. We are driven to replace these materials with our environmentally friendly hydrocarbon alternatives that reduce pollution at the source, and are proven to be more durable and efficient than incumbent materials. Ionomr's membranes and polymers are highly processable, which allow for simple integration into electrochemical systems. We enable optimal performance in applications for chemical & water remediation, energy storage and hydrogen. We are passionate about empowering the development of resilient and sustainable systems that will underlie the future of the renewable energy and circular chemical economies. | $14.9M / Series A / Jan 19, 2022 | |
Phoenix Molecular Designs
|
Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first- and best-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech,Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026 treating women with metastatic breast cancer. A Phase 1b mono-therapy trial in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States has also been completed with results providing further evidence of the benefit of inhibiting RSK in breast cancer. A phase 2a trial in HR+/HER2- metastatic breast cancer is currently underway at a number of leading academic research hospitals. RSK inhibition has also been proven to provide benefits in multiple hematologic cancers in the hematologic malignancies space as well. | $5M / Seed / Nov 20, 2019 | |
Keela
|
Keela is a fundraising CRM that unifies fundraising and donor communications. Keela’s uniquely powerful solution bridges the gap between fundraising and comms, allowing nonprofits to improve donor relations through targeted, multi-channel approaches. Keela's platform allows you to pull critical donor information directly from your CRM intoyour donor communications, so you know who to ask for a donation, the best time to ask them, and the perfect amount to ask for. | $1.5M / Seed / Sep 19, 2018 | |
|
Phoenix Molecular Designs
|
Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first- and best-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech,Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026 treating women with metastatic breast cancer. A Phase 1b mono-therapy trial in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States has also been completed with results providing further evidence of the benefit of inhibiting RSK in breast cancer. A phase 2a trial in HR+/HER2- metastatic breast cancer is currently underway at a number of leading academic research hospitals. RSK inhibition has also been proven to provide benefits in multiple hematologic cancers in the hematologic malignancies space as well. | $2.7M / Seed / Sep 18, 2018 | |
Hack Capital Ventures
|
Hack Capital is a software company that helps digital companies hire, train, retain, and motivate employees to do the best work of their lives. The company is building vertically integrated systems of intelligence that will help startup companies, as they grow, to manage their scale intelligently. | $750K / Seed / Feb 13, 2018 | |
ViralGains
|
ViralGains is a video ad journey platform that enables marketers to engage people with relevant brand stories in the contexts that people most favor. Using the platform to engage in a two-way conversation, brands discover exactly what people want and how they feel and build a unique journey that connects highly qualified consumers with relevantmessages that generate awareness, motivate intent, and impact purchase decisions. ViralGains is headquartered in Boston, with regional offices in Chicago, Detroit, Los Angeles, San Francisco, and New York. | $2.8M / Seed / Jul 31, 2014 | |
TradingView
|
TradingView is a network of traders and investors – powered by real-time data and market-leading analysis software. It’s a word-of-mouth success story: from TechStars in Chicago in 2013, to over 15 million monthly active site users and over 40,000 publishers, brokerages, and fintech utilizing its investing tools. TradingView is a global team ofover 200+, founded by Stan Bokov, Denis Globa, and Constantin Ivanov. In 2018 TradingView completed a $37 million Series B round led by Insight Partners, and in 2019 they acquired TradeIT in order to accelerate the company’s existing vision. | $652.5K / Seed / Jan 08, 2014 |
Co-Investors
About Creative Destruction Lab
Creative Destruction Lab (CDL) is a no-fee/no-equity organization that delivers an objectives-based mentoring program for massively scalable, pre-seed stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. Founded in 2012 byProfessor Ajay Agrawal at the University of Toronto’s Rotman School of Management, the program has expanded to thirteen sites across seven countries: Seattle, Oxford, Paris, Atlanta, Estonia, Wisconsin, Vancouver, Calgary, Montreal, Berlin, Melbourne and Halifax.
Creative Destruction Lab Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anthony K. Tjan
Fellow
|
|||
Daniel Mulet Lind
Associate Director, Quantum Machine Learning
|
|||
Dennis Bennie
Founding Partner and Associate
|
|||
Dennis Kavelman
Founding Partner and Associate
|
|||
Frank Sobey
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Christopher Bissonnette invest in?
Christopher Bissonnette invests primarily in Software, Enterprise Software and Information Technology startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Christopher Bissonnette's check size?
Christopher Bissonnette typically joins rounds of $653k–$5M at Seed and $15M–$20M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Christopher Bissonnette participates in.
How do I contact Christopher Bissonnette?
Public channels for Christopher Bissonnette include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christopher Bissonnette last invest?
The most recent investment recorded for Christopher Bissonnette closed in Dec 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
